Summit Therapeutics (SMMT) Assets Average (2020 - 2026)
Summit Therapeutics' (SMMT) quarterly Assets Average came in at $700.0 million in Q2 2026, up 97.79% YoY from $353.9 million in Q2 2025, and little changed on a QoQ basis from $699.5 million in Q1 2026.
Summit Therapeutics (SMMT) Assets Average (2020 - 2026) Analysis & Trends
Summit Therapeutics (SMMT) has 7 years of Assets Average data on file, last reported at $700.0 million in Q2 2026.
- Quarterly Assets Average rose 97.79% year-over-year to $700.0 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $700.0 million (up 97.79% YoY) and the FY2025 annual result came in at $593.4 million, up 85.86% from the prior year.
- Assets Average steadied at $700.0 million in Q2 2026, from $699.5 million in the prior quarter.
- In the past five years, Assets Average ranged from a high of $700.0 million in Q2 2026 to a low of $106.1 million in Q2 2022.
- A 5-year average of $344.7 million and a median of $323.4 million in 2025 frame the typical range for Assets Average.
- Annual changes were most pronounced in 2023 — Assets Average surged 299.86% — and 2024, when it tumbled 58.68%.
- Tracing SMMT's Assets Average over 5 years: stood at $409.7 million in 2022, then plunged by 48.58% to $210.7 million in 2023, then jumped by 122.68% to $469.2 million in 2024, then advanced by 7.94% to $506.5 million in 2025, then soared by 38.22% to $700.0 million in 2026.
- The last three Assets Average figures came in at $700.0 million (Q2 2026), $699.5 million (Q1 2026), and $506.5 million (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 3.29 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.86 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 16.08 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.34 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.09 Bn |
| 10 | Summit Therapeutics | 10.59 Bn | 9.90 Bn | - | 700.02 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 700.02 Mn |
| Mar 31, 2026 | 699.52 Mn |
| Dec 31, 2025 | 506.46 Mn |
| Sep 30, 2025 | 292.88 Mn |
| Jun 30, 2025 | 353.93 Mn |
| Mar 31, 2025 | 409.69 Mn |
| Dec 31, 2024 | 469.21 Mn |
| Sep 30, 2024 | 422.35 Mn |
| Jun 30, 2024 | 259.32 Mn |
| Mar 31, 2024 | 189.87 Mn |
| Dec 31, 2023 | 210.71 Mn |
| Sep 30, 2023 | 227.92 Mn |
| Jun 30, 2023 | 246.13 Mn |
| Mar 31, 2023 | 459.53 Mn |
| Dec 31, 2022 | 409.75 Mn |
| Sep 30, 2022 | 125.52 Mn |
| Jun 30, 2022 | 106.10 Mn |
| Mar 31, 2022 | 114.92 Mn |
| Dec 31, 2021 | 121.02 Mn |
| Sep 30, 2021 | 137.10 Mn |